** Shares of Tvardi Therapeutics TVRD.O rise 4.5% to $27.40
** Piper Sandler initiates coverage of TVRD with an "overweight" rating and PT of $78
** Piper believes that TVRD's lead drug, TTI-101, is positioned to drive broad improvement with an optimal profile
** TTI-101 is uniquely positioned to drive meaningful anti-fibrotic effects for idiopathic pulmonary fibrosis $(IPF.UK)$, a chronic lung disease, at cellular and immune levels - brokerage
** TVRD is developing TTI-109 as a next generation STAT3 inhibitor, with investigational new drug application submitted in June 2025
** TTI-109 offers a significant pipeline opportunity for TVRD with an optimized product profile and extended coverage to ensure sustained use over time - Piper Sandler
** TVRD stock up ~43% YTD, as of last close
(Reporting by Juby Babu in Mexico City)
((Juby.Babu@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.